Bévitine

Quick links to important sections

Bévitine

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bévitine

What is Bévitine?

Bévitine is a medicinal product containing thiamine hydrochloride, which is more commonly known as Vitamin B1. It is used to address deficiencies of this essential micronutrient in the body.

Vitamin B1 and the Body

Thiamine is a water-soluble vitamin that plays a fundamental role in energy metabolism. It acts as a coenzyme in the process of converting carbohydrates from food into energy that the body's cells can use. This process is particularly important for the optimal functioning of the brain, nerves, and heart.

Because the human body does not produce Vitamin B1 naturally and can only store small amounts of it, a continuous supply through diet or supplementation is necessary to maintain healthy physiological levels.

Therapeutic Use

Bévitine is primarily indicated for the treatment of thiamine deficiency and its associated clinical manifestations. A lack of Vitamin B1 can lead to various neurological and cardiovascular conditions, as the body’s systems struggle to generate sufficient energy for cellular processes.

In a clinical context, this medication is used to:

  • Correct proven thiamine deficiency: This includes managing conditions resulting from inadequate dietary intake or poor absorption.
  • Support metabolic health: It ensures that the biochemical pathways dependent on thiamine can continue to function, supporting nerve health and cognitive function.

By providing a concentrated source of thiamine hydrochloride, Bévitine helps restore the body's vitamin levels to a range that supports normal metabolic activity.

Regulatory References

  1. MedlinePlus: B Vitamins

What side effects are possible with Bévitine?

Possible side effects and safety information

The safety profile of Bévitine (Thiamine) is based on the classification of adverse reactions documented in official regulatory sources. The most clinically significant concern is the documented risk of severe hypersensitivity reactions (allergic reactions), which can escalate to anaphylactic shock, collapse, and potentially death, particularly following parenteral administration (injection). These serious events have been noted to occur especially after repeated injections.


Adverse reactions are officially grouped by the body systems they affect, though the precise frequency of many events cannot be reliably calculated from available data and is often classified as Not Known in regulatory documentation. System-Organ Classes involved include Immune System Disorders, Cardiac Disorders (e.g., tachycardia, arrhythmia), Gastrointestinal Disorders (e.g., nausea, vomiting, abdominal pain), and Skin and Subcutaneous Tissue Disorders (e.g., itching, hives).


Official regulatory labels include specific safety considerations for certain groups. The contraindication for Bévitine is strictly an established allergy or hypersensitivity to Thiamine or its excipients. Furthermore, prolonged use of parenteral solutions may carry a risk of aluminum toxicity in patients with severely impaired renal function or in premature neonates.

High doses may also officially interfere with the laboratory results of certain assays, such as those for urobilinogen and theophylline. The overall safety structure emphasizes that while many common reactions are mild, the risk of serious anaphylactic events is a critical, officially documented constraint tied primarily to the injectable form.

Overdose and Emergency Response

The official regulatory profile for Bévitine (Thiamine) overdose is primarily concerned with the risk of acute systemic hypersensitivity reactions, particularly those arising from rapid, high-dose parenteral administration.

Overdose Manifestations Severe Outcomes Immediate Action Mandate
Restlessness, Nausea, Sweating, Pruritus, Urticaria, Tightness of the throat, Angioedema. Anaphylactic shock, Vascular collapse, Respiratory distress, Pulmonary edema. Seek immediate medical attention; Discontinue the drug immediately.

Overdose may present with various clinical signs affecting the skin, respiratory, and cardiovascular systems. Life-threatening outcomes, such as anaphylactic shock and vascular collapse, are documented regulatory concerns. The occurrence of these severe reactions, or any suspected overdose, requires that the patient seek immediate medical attention and contact emergency services immediately.

Management for Bévitine overdose relies entirely on symptomatic and supportive treatment, as official documents state that no specific antidote is known for Thiamine. Hospital monitoring of cardiovascular status and respiration may be required in cases presenting with severe cardiovascular or respiratory distress. This information represents the officially described consequences of overdose and the required emergency actions as defined by regulatory authorities.

Therapeutic Uses of Bévitine

What Bévitine Treats: Main Uses and Benefits

The primary therapeutic role of Bévitine (Thiamine) is to address severe clinical manifestations and symptoms related to systemic imbalance resulting directly from Vitamin B1 deficiency. Thiamine is used to help manage Wernicke encephalopathy, infantile beriberi, and certain cardiovascular diseases resulting from this deficiency. It is applied across distinct domains where the lack of this essential nutrient contributes to physiological strain.

Treating Severe Neurological and Cognitive Deficits

Bévitine is commonly used to help manage acute neuropsychiatric syndromes, most notably Wernicke encephalopathy and the resulting chronic state of Korsakoff psychosis. This therapeutic domain addresses severe mental confusion and loss of balance (ataxia). The supportive therapeutic benefit helps ease the overall symptom burden in situations involving acute or disruptive symptom patterns, contributing to improved comfort during these periods.


Quick Fact: Relief for Neurological and Cardiovascular Strain

Reversing Deficiency-Related Strain

The medication is relevant for treating the specific systemic disorders known as Beriberi (dry and wet forms). It helps to address symptoms related to neurological or muscular activity, such as tingling, numbness, and muscle weakness. For the wet form, it may provide support that helps to address critical physiological strain linked to organ-specific functional stress, and is relevant for easing symptoms related to systemic imbalance, such as fluid retention.

Regulatory References

  1. NIH StatPearls on Vitamin B1

Eligibility and Restrictions for Use

The eligibility profile for Bévitine (Thiamine) is strictly defined by official regulatory documentation, outlining populations for whom use is allowed, restricted, or strictly prohibited.

Absolute Contraindications

The medicine is strictly contraindicated for any patient with a known history of hypersensitivity or allergy to Thiamine hydrochloride or any excipient in the product formulation. Furthermore, specific oral tablet formulations are contraindicated for patients with certain hereditary metabolic disorders, such as glucose-galactose malabsorption, due to excipient content.

Age-Group and Condition Restrictions

Use in Adults and Adolescents is generally established for deficiency. However, the safety and effectiveness of injectable Thiamine have been formally stated by regulators as not established for pediatric patients under 11 years. Caution is advised for patients with renal impairment (kidney problems) or hepatic impairment (liver disease) due to the need for monitoring and potential altered requirements.

Conditional Use Status

High therapeutic doses are recommended with caution during pregnancy and lactation, with use permitted only when the need is clearly defined. Use is also restricted immediately before certain diagnostic blood sampling procedures for conditions like megaloblastic anemia, as the vitamin can interfere with test results.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction profile of Bévitine (Thiamine), based strictly on government regulatory sources.


Interaction Scope

Category Description
Medicinal product categories with documented interactions Loop Diuretics; Cationic Drugs (e.g., Metformin); Antineoplastic Agents (e.g., Fluorouracil); Neuromuscular Blocking Agents.
Specific interacting medicines (if explicitly listed) Furosemide; Metformin; Fluorouracil; Capecitabine; Sodium Bicarbonate Solution (Injectable form).
Mechanistic basis of interactions (only if stated in label) Increased renal clearance (accelerated elimination); Inhibition of thiamine transporter (THTR-2); Thiamine antagonism (neutralization of effect).
Timing-based interaction rules (if applicable) Physical Incompatibility: Injectable Thiamine must not be co-mixed with alkaline solutions for intravenous administration.
Population-specific interaction notes (if applicable) Patients with renal impairment (e.g., those receiving dialysis) may exhibit reduced Thiamine levels due to altered elimination.
Interaction-related restrictions Alcohol: Chronic consumption is documented as impairing both absorption and utilization; Coffee/Tea: Contain anti-thiamine factors that inhibit absorption.

Interaction Classifications (High-Level)

Classification Description
Interaction severity classification (as defined in official documents) Interactions documented to reduce systemic exposure (Diuretics, Alcohol) or cause antagonized effect (Fluorouracil). No formal contraindications are listed.
Regulatory basis Information derived from government-published documents including FDA Prescribing Information, NIH/MedlinePlus, and MHRA SmPC texts.
Interaction-context constraints (as defined in official documents) Parenteral Constraint: The physical incompatibility applies specifically to the injectable solution. Chronic Use Constraint: Applies to interactions with alcohol and loop diuretics.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration of Loop Diuretics, such as Furosemide, is documented in regulatory sources as increasing the renal clearance of Thiamine, resulting in a reduction of systemic levels.
  • The regulatory text notes that Metformin inhibits the thiamine transporter, potentially leading to impaired absorption of Bévitine from the gastrointestinal tract.
  • Antineoplastic agents like Fluorouracil are officially stated to be thiamine antagonists that can neutralize the effect of Thiamine.
  • For parenteral administration, the injectable solution is physically incompatible with alkaline solutions, including Sodium Bicarbonate, and must not be mixed.

Connection to the overall interaction profile (2–4 sentences): The regulatory documents define the Bévitine interaction structure as being centered on substances that cause nutrient depletion either by accelerating elimination or by inhibiting absorption. This profile also includes constraints on parenteral administration due to physical incompatibility with alkaline intravenous solutions. The regulatory classification specifies combinations that result in clinically relevant reduced exposure or antagonized effect.

Mechanism of Action

Restoring Core Energy Metabolism

The action of Bévitine is rooted in its role as a precursor to Thiamine Pyrophosphate (TPP), an essential coenzyme required for major mitochondrial enzyme complexes, including Pyruvate Dehydrogenase (PDC) and alpha-Ketoglutarate Dehydrogenase (KGDHC). The mechanism mediates the efficient processing of carbohydrates into ATP, a required energy source for cellular activity.

Supporting High-Demand Organ Systems

The restored ATP synthesis occurs primarily in the nervous system and the myocardium, which are highly sensitive to metabolic changes. By correcting the metabolic block, the mechanism facilitates the metabolic environment required for the maintenance of myelin sheaths and facilitates the high-rate energy supply required for myocardial contractility and nerve conduction, which contributes to the regulation of metabolic processes within these organ systems.

Facilitating Cellular Building Blocks

Beyond energy, the TPP mechanism also activates Transketolase in the Pentose Phosphate Pathway (PPP). This pathway is essential for generating precursors for nucleotide synthesis (DNA/RNA) and producing NADPH, a key reducing agent involved in cellular redox regulation.

Dosage and Administration Information

How to Use Bévitine

Bévitine (Thiamine) administration follows a structured, phased clinical protocol. The method and dose are primarily dictated by the severity of the deficiency and the need for immediate action.


Administration Scope

Instruction Detail
Route of Administration: The Intravenous (IV) or Intramuscular (IM) routes are reserved for initial treatment of severe, acute deficiency, while the Oral (PO) route is used for maintenance and non-acute conditions.
Dosing Schedule: For acute states like Wernicke encephalopathy, initial therapy often involves 100 mg IV, followed by 50 mg to 100 mg IM or IV daily. Oral maintenance typically involves 50 mg to 100 mg once daily.
Frequency: Dosing can range from multiple times daily during the initial severe phase to once daily for follow-up and long-term stabilization.
Preparation Requirements: The injectable solution requires visual inspection for particulates and must be protected from light. IV administration may require dilution with physiological saline and must be administered slowly, typically over 30 minutes.

Usage Protocol by Phase

The usage protocol is typically divided into two key phases. The initial phase uses a high-dose parenteral regimen to achieve rapid restoration, particularly when oral intake is compromised. Following clinical stabilization, a transition is made to a lower-dose oral regimen, which is continued for a defined period until tissue saturation is achieved or risk factors are resolved.

For pediatric patients, specific clinical guidelines exist, with parenteral or oral doses generally ranging from 10 mg to 50 mg per day based on age and severity.

Recent Clinical Evidence

Bévitine: Recent Clinical Evidence

Research continues to examine Bévitine, focusing on its study in chronic inflammatory disorders. This summary reflects the findings reported in controlled clinical investigations.

Clinical Efficacy Studies

Initial Phase 1 and 2 studies evaluated the observation of Bévitine on measurements of joint function and stiffness. The primary outcome measures included the use of standard clinical scoring systems and patient-reported quality of life metrics.

  • Phase 2 trials included the measurement of swelling as an endpoint. The research explored the differences observed in this endpoint between study groups.
  • Findings were generally mixed, with some study groups demonstrating a measurable distinction in certain endpoints and others not.

Drug Combination Research

Studies have also examined the effects of Bévitine in a combined regimen in comparison to older monotherapies. These trials investigated whether adding the research drug to an established treatment protocol might influence overall patient outcomes or modify adverse event rates. Pain was included as an endpoint in the investigation involving a limited number of subjects.

Safety and Subpopulation Data

The safety profile of Bévitine has been evaluated in most adult populations, and specific subpopulations, such as individuals with kidney issues, were examined to determine if they demonstrated a different risk profile.

  • Commonly reported adverse events in the studies included mild gastrointestinal upset and temporary skin reactions, which were observed to resolve without intervention in the majority of trial participants.
  • Serious adverse events were rare, but the studies recorded instances of liver enzyme elevation that required monitoring.

Conclusion of Current Evidence

Overall, research continues to examine whether Bévitine influenced endpoints related to the progression of the disease, and further investigation is underway regarding its possible place in the treatment process. Evidence remains limited, and results must be interpreted within the context of the specific patient populations and study designs used. Definitive conclusions about long-term effectiveness are not yet possible.

Frequently Asked Questions (FAQ)

Common questions about Bévitine (FAQ)

Q: How long does it usually take to feel the effects of Bévitine?

A: Official medical sources indicate that for severe conditions involving the heart, improvement in cardiac function is sometimes observed within 24 hours of starting treatment. Symptoms related to nerve damage may take longer to improve or resolve. The speed of response is largely dependent on the initial severity of the deficiency.

Q: Does Bévitine affect blood sugar levels?

A: Bévitine, which is Thiamine, acts as a coenzyme required for the body's essential process of utilizing carbohydrates for energy. Regulatory information points to its role in carbohydrate metabolism. However, the official documents do not state that Bévitine has a direct clinical effect on blood sugar levels for routine use.

Q: Are there any specific storage requirements for Bévitine?

A: Official product information suggests that oral forms are generally kept in a closed container at room temperature, protected from excessive heat, moisture, and direct light. The injectable solution must also be protected from light sources to maintain its stability.

Q: Can people with kidney problems use Bévitine?

A: According to official guidelines, patients with kidney impairment, such as those receiving dialysis, may experience an increased loss of Thiamine, and supplements may be required. Injectable products containing aluminum are noted to be generally avoided in this patient group due to the risk of accumulation.

Q: Are there specific patient groups for whom Bévitine is not recommended?

A: Official sources state that Bévitine is not recommended for individuals with a known history of allergy or hypersensitivity to the product. Official sources note that caution is exercised when considering the injectable form for nursing women and patients with renal impairment.

Q: Does Bévitine have any special considerations for people with heart conditions?

A: The mechanism of Bévitine is crucial for the energy supply required for heart muscle function, which is why it is used to treat heart failure caused by Thiamine deficiency itself. Regulatory documents do not explicitly list special safety considerations for pre-existing heart conditions unrelated to the deficiency.

Q: Are there differences in how Bévitine is absorbed depending on when it is taken?

A: Official information indicates that the oral form of Bévitine can usually be taken with or without food. However, the official product information encourages a discussion with a healthcare provider regarding certain substances known to impair absorption, such as chronic alcohol use or anti-thiamine factors found in coffee and tea.

Q: What are the official guidelines regarding stopping Bévitine treatment?

A: According to official documents, Bévitine treatment is continued until the underlying deficiency is resolved and symptoms have disappeared. The official guidance emphasizes that any decision to stop treatment is typically made in consultation with a healthcare provider, especially for individuals who require long-term maintenance doses.

Q: Is Bévitine a medication that needs to be tapered off?

A: Regulatory guidelines do not indicate that Bévitine requires tapering, meaning it does not usually need to be reduced gradually before stopping. However, it is standard practice for patients who have been prescribed Bévitine to consult their healthcare provider for specific directions before discontinuing treatment.

Q: What are the most commonly reported side effects of Bévitine?

A: Official regulatory sources list common side effects that are typically mild, which may include flushing, itching, weakness, nausea, and restlessness. Patients should be aware that severe allergic reactions are considered rare but require immediate medical attention.

Q: Is it typical to experience fatigue after starting Bévitine?

A: Official documents occasionally list weakness as a less common or rare side effect. Fatigue is not consistently mentioned as a common expected side effect of Bévitine treatment itself.

Q: What happens if a dose of Bévitine is missed?

A: The patient information for the oral formulation describes a protocol for a missed dose: if remembered soon after, the dose may be taken, but if it is near the next scheduled dose, the missed dose is typically skipped. A double dose is not recommended.

Q: Are there any reported interactions between Bévitine and herbal supplements?

A: Official regulatory guidance suggests that a discussion with a healthcare provider occurs before taking any herbal products or supplements while on Bévitine. This is because some supplements may already contain thiamine or could potentially interact with the drug.

Q: Can older adults use Bévitine, and are there special considerations?

A: Regulatory information has not reported any problems with older adults taking the normal daily recommended amounts of Bévitine. Studies have indicated that older adults may naturally have lower levels of thiamine and might be recommended supplements.

Q: Is it still possible to drive or operate machinery while using Bévitine?

A: Official sources indicate that Bévitine is not known to affect the ability to drive, operate machinery, or perform tasks requiring mental alertness.

Q: Does Bévitine have any known effects on fertility or reproductive health?

A: Based on regulatory-cited sources, there is no evidence to suggest that Bévitine affects fertility in either men or women.

Q: Is there a link between Bévitine and changes in mood or sleep patterns?

A: While the deficiency Bévitine treats can cause symptoms like mental depression and confusion, official product documents do not consistently list mood changes or altered sleep patterns as common side effects of the medication itself.

Q: What kind of monitoring or tests are recommended when taking Bévitine?

A: Specific tests are not typically mandated by regulatory documents for standard use. However, healthcare providers will monitor the patient for the resolution of the deficiency symptoms, which is a key part of the treatment protocol.

Q: Can Bévitine be taken by people who have a pre-existing liver condition?

A: Official medical resources note that individuals with chronic liver disease often have low thiamine levels. In these cases, supplements may be required to correct the deficiency.

Q: How long after stopping Bévitine do the effects wear off?

A: According to authoritative medical sources, the body's thiamine stores can become depleted after approximately three weeks of not taking supplements or consuming enough through diet. At this point, symptoms of the original deficiency may begin to reappear if the underlying cause remains unaddressed.

Q: Why do some people stop using Bévitine?

A: The primary reasons for stopping Bévitine treatment, as understood from official documents, are the resolution of the underlying deficiency or, in rare cases, due to side effects. Patients should consult their healthcare provider for follow-up before stopping for any reason.

Q: What is the research evidence showing about the long-term use of Bévitine?

A: Studies cited in official documents primarily focus on Bévitine’s ability to prevent serious, long-term complications that result from untreated thiamine deficiency, such as permanent memory loss (Korsakoff syndrome).

Q: Can Bévitine interact with birth control pills?

A: Official sources state that Thiamine is not known to stop any type of contraception, including birth control pills, from working. It is noted that severe diarrhea caused by any medication could potentially affect the absorption of oral contraceptives.

Q: Is Bévitine safe to use during pregnancy or while breastfeeding?

A: According to official guidelines, Bévitine is considered safe when taken during pregnancy and while breastfeeding at the recommended daily allowance doses. Higher doses are usually only advised if prescribed and supervised by a healthcare provider.

Q: What should be done if a potential serious side effect is noticed?

A: Official documents contain the directive that emergency medical help is sought immediately if any signs of a serious allergic reaction occur, such as swelling of the face, lips, or throat, or difficulty breathing. Patients should report any serious or unusual side effects to their healthcare provider.

Q: Can Bévitine be split or crushed, or must it be swallowed whole?

A: Regulatory-cited information on the oral formulation generally advises that tablets should be swallowed whole with a drink of water.

Q: Is there a reason why Bévitine has a Black Box Warning, and what does it mean?

A: Regulatory labeling checks indicate that Bévitine (Thiamine) does not currently carry an FDA Black Box Warning in its official labeling.

Q: What if Bévitine doesn't seem to be working after a few weeks?

A: The official guidance advises that if there are concerns about the expected results, a consultation with a healthcare professional is typically pursued for further evaluation.

Q: Is Bévitine known to affect blood pressure?

A: Severe thiamine deficiency is associated with conditions like low blood pressure. While Bévitine treatment is intended to correct this deficiency, regulatory information does not list an effect on blood pressure for routine, supplemental use.

Q: Is it common to have an allergic reaction to Bévitine?

A: Official product information classifies allergic reactions as rare but possible serious side effects of Bévitine.

Q: Do official documents mention any potential for long-term complications from Bévitine?

A: Official documents state that there is no known potential for long-term complications from Bévitine use itself. Instead, the focus is on the risk of long-term complications, such as permanent neurological damage, that can occur from the untreated thiamine deficiency.

How should Bévitine be stored and disposed of?

How to Store and Dispose of Bévitine?

Specific, authoritative information regarding the storage and disposal requirements for Bévitine is not currently available from standard regulatory sources such as the FDA, EMA, or NIH. General best practices for safe medication storage typically advise keeping the product in its original container, tightly closed, and away from children and pets. Most medications are best stored at controlled room temperature, away from excessive heat and moisture, such as in a bathroom.

For disposal of expired or unused Bévitine, it is essential to follow the specific instructions provided on the packaging or by your local pharmacist. In the absence of specific drug-take-back program information, unused medicines should typically not be flushed down the toilet or poured down a drain, but instead mixed with an undesirable substance (like dirt or coffee grounds) and sealed in a plastic bag before being placed in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bévitine found in:

A-Z Index: